| Literature DB >> 35262077 |
Amanda P Smith1, Evan P Williams2, Taylor R Plunkett2, Muneeswaran Selvaraj3, Lindey C Lane4, Lillian Zalduondo2, Yi Xue2, Peter Vogel5, Rudragouda Channappanavar2,3,6, Colleen B Jonsson2,6, Amber M Smith1,2,6.
Abstract
Secondary bacterial infections can exacerbate SARS-CoV-2 infection, but their prevalence and impact remain poorly understood. Here, we established that a mild to moderate SARS-CoV-2 infection increased the risk of pneumococcal coinfection in a time-dependent, but sexindependent, manner in the transgenic K18-hACE mouse model of COVID-19. Bacterial coinfection was not established at 3 d post-virus, but increased lethality was observed when the bacteria was initiated at 5 or 7 d post-virus infection (pvi). Bacterial outgrowth was accompanied by neutrophilia in the groups coinfected at 7 d pvi and reductions in B cells, T cells, IL-6, IL-15, IL-18, and LIF were present in groups coinfected at 5 d pvi. However, viral burden, lung pathology, cytokines, chemokines, and immune cell activation were largely unchanged after bacterial coinfection. Examining surviving animals more than a week after infection resolution suggested that immune cell activation remained high and was exacerbated in the lungs of coinfected animals compared with SARS-CoV-2 infection alone. These data suggest that SARS-CoV-2 increases susceptibility and pathogenicity to bacterial coinfection, and further studies are needed to understand and combat disease associated with bacterial pneumonia in COVID-19 patients.Entities:
Year: 2022 PMID: 35262077 PMCID: PMC8902874 DOI: 10.1101/2022.02.28.482305
Source DB: PubMed Journal: bioRxiv